SCM
MCRB icon

Soleus Capital Management’s Seres Therapeutics MCRB Stock Holding History

Soleus Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-91,049
Closed -$4.33M – 94
2023
Q3 		$4.33M Sell
91,049
-11,250
-11% -$859K 0.4% 60
2023
Q2 		$9.8M Buy
+102,299
New +$11.1M 1.09% 29

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Soleus Capital Management's MCRB Position: Q4 2023 in Review

Soleus Capital Management sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 91,049 shares — an estimated $4.33M sold.

Soleus Capital Management first reported a position in MCRB in Q2 2023 and held it in 2 quarters. The position peaked at $9.8M in Q2 2023. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

  • Soleus Capital Management reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Soleus Capital Management sold 91,049 Seres Therapeutics shares in Q4 2023, an estimated $4.33M.
  • Soleus Capital Management first reported a position in Seres Therapeutics in Q2 2023 and held it in 2 quarters.
  • Soleus Capital Management's Seres Therapeutics position peaked at $9.8M in Q2 2023.
  • 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on Soleus Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.